JP2007506681A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007506681A5 JP2007506681A5 JP2006527166A JP2006527166A JP2007506681A5 JP 2007506681 A5 JP2007506681 A5 JP 2007506681A5 JP 2006527166 A JP2006527166 A JP 2006527166A JP 2006527166 A JP2006527166 A JP 2006527166A JP 2007506681 A5 JP2007506681 A5 JP 2007506681A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- use according
- medicament
- asthma
- daclizumab
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50588303P | 2003-09-23 | 2003-09-23 | |
| US55297404P | 2004-03-12 | 2004-03-12 | |
| PCT/US2004/031640 WO2005030252A1 (en) | 2003-09-23 | 2004-09-21 | Treatment of respiratory diseases with anti-il-2 receptor antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007506681A JP2007506681A (ja) | 2007-03-22 |
| JP2007506681A5 true JP2007506681A5 (enExample) | 2007-11-08 |
Family
ID=34396276
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006527166A Pending JP2007506681A (ja) | 2003-09-23 | 2004-09-21 | 抗ｉｌ−２受容体抗体による呼吸器疾患の治療 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20050089517A1 (enExample) |
| EP (1) | EP1675615A1 (enExample) |
| JP (1) | JP2007506681A (enExample) |
| AU (1) | AU2004275860A1 (enExample) |
| BR (1) | BRPI0414688A (enExample) |
| CA (1) | CA2538737A1 (enExample) |
| RU (1) | RU2006113701A (enExample) |
| WO (1) | WO2005030252A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7932365B2 (en) | 2003-11-08 | 2011-04-26 | Pro Thera Biologics, Llc | Preparation and composition of inter-alpha inhibitor proteins from human plasma for therapeutic use |
| JP5793076B2 (ja) | 2008-05-28 | 2015-10-14 | プロセラ バイオロジクス， インコーポレイテッド | 血液由来インター−アルファ−阻害タンパク質の調製及び組成物。 |
| AU2009325088B2 (en) * | 2008-12-10 | 2014-06-19 | Duke University | Inhibition of inter-alpha trypsin inhibitor for the treatment of airway disease |
| EP2710384B1 (en) * | 2011-05-12 | 2017-11-08 | Temple University - Of The Commonwealth System of Higher Education | Diagnosis and treatment of copd |
| US9572872B2 (en) | 2012-09-09 | 2017-02-21 | Prothera Biologics, Inc. | Treatment of disease using inter-alpha inhibitor proteins |
| CA3036553A1 (en) | 2016-09-13 | 2018-03-22 | Prothera Biologics, Inc. | Methods for treating pulmonary disease using inter-alpha inhibitor proteins |
| CN110177564A (zh) | 2016-12-13 | 2019-08-27 | 德里尼亚公司 | 多价的调节t细胞调节剂 |
| KR102587810B1 (ko) | 2017-04-25 | 2023-10-11 | 프로테라 바이오로직스, 인크. | 인터-알파 억제제 단백질을 정량화하는 방법 |
| WO2020140040A1 (en) * | 2018-12-29 | 2020-07-02 | Kaleo, Inc. | Devices and methods for delivery of substances within a prefilled syringe |
| CN114641283B (zh) * | 2019-10-04 | 2024-07-12 | R.P.谢勒技术有限责任公司 | 抗cd25抗体-美登素偶联物及其使用方法 |
| US12268847B1 (en) | 2021-02-10 | 2025-04-08 | Kaleo, Inc. | Devices and methods for delivery of substances within a medicament container |
| GB202106254D0 (en) * | 2021-04-30 | 2021-06-16 | Teva Uk Ltd | Inhaler system |
| CN118370816A (zh) * | 2024-03-22 | 2024-07-23 | 中日友好医院(中日友好临床医学研究所) | Il-2/抗il-2抗体免疫复合物的应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4473493A (en) * | 1981-04-29 | 1984-09-25 | Immunex Corporation | Hybridoma antibody which inhibits interleukin 2 activity |
| US4411993A (en) * | 1981-04-29 | 1983-10-25 | Steven Gillis | Hybridoma antibody which inhibits interleukin 2 activity |
| US4845198A (en) * | 1984-05-21 | 1989-07-04 | Immunex Corporation | Hybridoma antibody which binds IL-2 receptor |
| US5336489A (en) * | 1985-09-05 | 1994-08-09 | The Beth Israel Hospital Association | Treatment of allograft rejection with IL-2 receptor-specific cytotoxins |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| WO1992008474A2 (en) * | 1990-11-20 | 1992-05-29 | The National Heart & Lung Institute | Treatment of lung diseases |
| MX9707862A (es) * | 1995-04-14 | 1997-11-29 | Glaxo Wellcome Inc | Inhalador de dosis medida para el propionato de fluticasona. |
| US6013256A (en) * | 1996-09-24 | 2000-01-11 | Protein Design Labs, Inc. | Method of preventing acute rejection following solid organ transplantation |
| DE69937057T2 (de) * | 1998-07-27 | 2008-05-29 | Novartis Ag | Verwendung von basiliximab zur behandlung von rheumatoider arthritis und hauterkrankungen |
| WO2002081508A2 (en) * | 2001-04-06 | 2002-10-17 | University Of Bristol | Use of cd25 binding molecules in steroid-resistant patients |
| AU2003295471B2 (en) * | 2002-11-15 | 2011-08-25 | Genmab A/S | Human monoclonal antibodies against CD25 |
-
2004
- 2004-09-21 RU RU2006113701/15A patent/RU2006113701A/ru not_active Application Discontinuation
- 2004-09-21 US US10/947,432 patent/US20050089517A1/en not_active Abandoned
- 2004-09-21 JP JP2006527166A patent/JP2007506681A/ja active Pending
- 2004-09-21 EP EP04785126A patent/EP1675615A1/en not_active Withdrawn
- 2004-09-21 AU AU2004275860A patent/AU2004275860A1/en not_active Abandoned
- 2004-09-21 WO PCT/US2004/031640 patent/WO2005030252A1/en not_active Ceased
- 2004-09-21 BR BRPI0414688-3A patent/BRPI0414688A/pt not_active IP Right Cessation
- 2004-09-21 CA CA002538737A patent/CA2538737A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102390714B1 (ko) | 벤랄리주맙을 이용하여 천식의 악화 속도를 감소시키는 방법 | |
| JP2015527364A5 (enExample) | ||
| JP2017507139A5 (enExample) | ||
| RU2015109716A (ru) | Способы лечения или предотвращения астмы посредством введения антагониста il-4r | |
| JP2009511480A5 (enExample) | ||
| JP2006527193A5 (enExample) | ||
| CN107073114B (zh) | 使用瑞利珠单抗治疗中度到重度嗜酸细胞性哮喘 | |
| RU2006113701A (ru) | Лечение респираторных заболеваний антителами против рецептора il-2 | |
| IL271132B1 (en) | Dry powder aclidinium salt pharmaceutical composition for treatment of copd | |
| HK1225302A1 (en) | Methods for reducing exacerbation rates of asthma using benralizumab | |
| JP2019528316A5 (enExample) | ||
| JP2016534996A5 (enExample) | ||
| KR102337601B1 (ko) | 벤랄리주맙을 이용하여 천식 증상을 개선시키는 방법 | |
| JP2015511625A5 (enExample) | ||
| CA2568571A1 (en) | Combinations comprising antimuscarinic agents and corticosteroids | |
| JP2008110991A (ja) | 処置方法 | |
| JP2013525310A5 (enExample) | ||
| EP4267184B1 (en) | Interleukin 5 binding protein dosage regimen | |
| TWI870471B (zh) | 全身性硬化症治療用醫藥組合物 | |
| Kuhn | Immunoglobulin E blockade in the treatment of asthma | |
| Masekela et al. | Asthma treatment in children: A pragmatic approach | |
| EP3957364A1 (en) | A binding molecule specifically binding to human cd4 for use in the treatment of pulmonary diseases | |
| JP6021952B2 (ja) | 慢性閉塞性肺疾患の治療法 | |
| Nair et al. | B32-37 Safety and Efficacy of Omalizumab in Severe Asthma Patients With Elevated IgE Levels: A Two-year Retrospective Review From Mumbai | |
| WO2026024319A1 (en) | Treatment of obesity and obstructive sleep apnea |